Rhythm Pharmaceuticals Valuation
Is RYTM * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RYTM * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RYTM * (MX$680.21) is trading below our estimate of fair value (MX$3382.56)
Significantly Below Fair Value: RYTM * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RYTM *?
Other financial metrics that can be useful for relative valuation.
What is RYTM *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$2.24b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 23.4x |
Enterprise Value/EBITDA | -8x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does RYTM *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 21.3x | ||
BEAM Beam Therapeutics | 5.3x | -31.4% | US$1.9b |
AGIO Agios Pharmaceuticals | 60.8x | 48.8% | US$1.8b |
688520 Sinocelltech Group | 9.1x | 26.7% | CN¥19.9b |
ARDX Ardelyx | 9.9x | 32.8% | US$1.6b |
RYTM * Rhythm Pharmaceuticals | 24.4x | 44.7% | Mex$2.2b |
Price-To-Sales vs Peers: RYTM * is good value based on its Price-To-Sales Ratio (24.4x) compared to the peer average (33.1x).
Price to Earnings Ratio vs Industry
How does RYTM *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: RYTM * is expensive based on its Price-To-Sales Ratio (24.4x) compared to the Global Biotechs industry average (10x).
Price to Sales Ratio vs Fair Ratio
What is RYTM *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 24.4x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate RYTM *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.